Losartan Potassium Tablet, Film Coated
Product Images NDC 87441-053

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 87441-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium 50 mg (8744105301 Losartan Potassium 50 mg)

Losartan Potassium 50 mg (8744105301 Losartan Potassium 50 mg)
This text appears to be a prescription label for Losartan Potassium tablets. It contains information about the dosage, storage conditions, and the distributor of the medication. The label instructs the pharmacist to dispense the tablets to each patient along with an accompanying Medication Guide. It also provides details about the dosage and usage which can be found in the package insert. The medication is to be stored at a temperature between 20°C to 25°C (68°F to 77°F).*
FDA Label Image

Figure1 (Losartan Fig1)

Figure1 (Losartan Fig1)
This text mentions two medications: Atenolol and Losartan Potassium. The adjusted risk reduction is stated to be 13%. Additionally, there is a timeline provided with study months listed from 6 to 66.*
FDA Label Image

Figure2 (Losartan Fig2)

Figure2 (Losartan Fig2)
This text provides data on the comparative effects of Atenolol and Losartan Potassium on the percentage of patients experiencing fatal/non-fatal strokes over a 66-month study period. The timeline at the bottom indicates the duration in months of the study.*
FDA Label Image

Figure 3 (Losartan Fig3)

FDA Label Image

Figure-4 (Losartan Fig4)

Figure-4 (Losartan Fig4)
This text provides information about the percentage of patients experiencing an event, the risk reduction percentage, and the statistical significance of the results in a comparative study between Losttan Potassium and a placebo. The risk reduction achieved with Losttan Potassium is 16.1%, with a p-value of 0.022 indicating statistical significance.*
FDA Label Image

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.